Dionem is indicated in the treatment of the following infections- Complicated Intra-Abdominal Infections : Complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides ... Read more Dionem is indicated in the treatment of the following infections- Complicated Intra-Abdominal Infections : Complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vuigatus, Streptococcus intermedius, Streptococcus consteilatus and Peptostreptococcus micros. Complicated Urinary Tract Infections, Including Pyelonephritis : Complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Acinetobacter baumannii.
Doripenem is a broad-spectrum carbapenem class of antibacterial with activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria.Doripenem exerts its bactericidal activity by inhibiting bacterial cell wall biosynthesis. Doripenem inactivates multiple essential penicillin-binding proteins (PBPs) resulting in inhibition of cell wall synthesis with subsequent cell death. In E. coli and P. aeruginosa,Doripenem binds to PBP 2, which involved in the maintenance of cell shape, as well as to PBPs 3 and 4. Absorption : Mean plasma concentrations of Doripenem following a single 1-hour intravenous infusion of a 500 mg dose to 24 healthy subjects is 23.0 (6.6) pg/mL. The pharmacokinetics of Doripenem (Cmax and AUC) are linear over a dose range of 500 mg to 1 g when intravenously infused over 1 hour. There is no accumulation of Doripenem following multiple intravenous infusions of either 500 mg or 1 g administered every 8 hours for 7 to 10 days in subjects with normal renal function. Distribution : The average binding of Doripenem to plasma proteins is approximately 8.1% and is independent of plasma drug concentrations. The median (range) volume of distribution at steady state in healthy subjects is 16.8 L (8.09-55.5 L), similar to extracellular fluid volume (18.2 L). Metabolism : Metabolism of doripenem to a microbiologically inactive ring-opened metabolite (doripenem-M1) occurs primarily via dehydropeptidase-l. In pooled human liver microsomes, no in vitro metabolism of Doripenem could be detected, indicating that Doripenem is not a substrate for hepatic CYP450 enzymes. Excretion : Doripenem is primarily eliminated unchanged by the kidneys. The mean plasma terminal elimination half-life of Doripenem in healthy non-elderly adults is approximately 1 hour and mean (SD) plasma clearance is 15.9 (5.3) L/hour. Mean renal clearance is 10.8 (3.5) L/hour. In healthy adults given a single 500 mg dose a mean of 70% and 15% of the dose was recovered in urine as unchanged drug and the ring-opened metabolite, respectively, within 48 hours.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
The recommended dosage of Doripenem is 500 mg administered every 8 hours by intravenous infusion over one hour in patients >18 years of age- Complicated intra-abdominal infection : 500 mg every 8 hours for 5-14 days. Infusion time: 1 hour. Complicated UTI, including pyelonephritis : 500 mg every 8 hours for 10 days. Infusion time: 1 hour. Dosage of Doripenem in patients with renal impairment- CrCI >50 mL/min : No dosage adjustment necessary CrCI ≥30 to ≤ 50 mL/min : 250 mg administered intravenously (over 1 hour) every 8 hours. CrCI >10 to <30 mL/min : 250 mg administered intravenously (over 1 hour) every 12 hours. Geriatric Patients : No dosage adjustment is recommended for elderly patients with normal (for their age) renal function.
Headache Diarrhea Nausea Phlebitis Rash Vulvomycotic infection
Doripenem is contraindicated in patients with known serious hypersensitivity to any component of the product or to other drugs in the same class or patients who have demonstrated anaphylactic reactions to beta-lactams.
Increased plasma concentration with probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
Serious and occasionally fatal hypersensitivity (anaphylactic) and serious skin reactions have been reported in patients receiving beta-lactam antibiotics. Before therapy with Dionem is instituted, careful inquiry should be made concerning a previous history of hypersensitivity reactions to other active substances in this class or to beta-lactam antibiotics. Dionem should be used with caution in patients with such a history. Should a hypersensitivity reaction to Dionem occur, it should be discontinued immediately and appropriate measures should be taken. Serious acute hypersensitivity (anaphylactic) reactions require immediate emergency treatment.